AstraZeneca bolsters COVID therapeutics with RQ Bio deal

A healthcare employee holds a vial of the AstraZeneca vaccine throughout a ceremony to announce the AstraZeneca vaccine being produced within the nation by Fiocruz Institute, in Brasilia, Brazil February 22, 2022. REUTERS/Adriano Machado/File Photograph

LONDON: AstraZeneca is paying as much as $157 million, plus royalties, for an unique licence to develop and promote a set of pre-clinical COVID antibody therapies developed by RQ Bio, the London-based biotech mentioned on Tuesday.

The experimental antibody therapies embody these designed to focus on folks with compromised immune programs – reminiscent of AstraZeneca’s personal antibody cocktail, Evusheld, which is already authorized in a number of nations,

AstraZeneca not too long ago signalled its curiosity in beefing up its roster of immune-focused therapies after carving out a brand new reporting unit in its quarterly stories entitled “Vaccines & Immune Therapies” that embody its COVID merchandise.

The corporate is banking Evusheld to partially offset its quickly shrinking gross sales of its COVID vaccine, which was its second bestseller final yr however has struggled to compete with rivals made by Pfizer and Moderna, and has hit setbacks with manufacturing, uncommon side-effects and comparatively restricted shelf life. 

See also  Wall St Week Forward: Recession? Mushy touchdown? Stagflation? Buyers assess economic system's power